Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

Ibrahim Aldoss; Bijal D. Shah; Jae H. Park; Lori Muffly; Aaron C. Logan; Patrick Brown; Wendy Stock; Elias J. Jabbour

doi:10.1002/ajh.26853

Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

Ibrahim Aldoss, Bijal D. Shah, Jae H. Park, Lori Muffly, Aaron C. Logan, Patrick Brown, Wendy Stock, Elias J. Jabbour

Leukemia

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

The recent approvals of four CD19-or CD22-targeted therapies for B-cell acute lymphoblastic leukemia (B-ALL) have transformed the treatment of relapsed/refractory (r/r) disease. Adults with r/r B-ALL are usually eligible for all options, but there are no studies directly comparing these agents, and the treating physician must decide which to select. Each therapy has notable activity as a single agent but has limitations in particular settings, and the optimal choice varies. These therapies can be complementary and used either sequentially or concomitantly. Here, we review the current landscape of antigen-targeted therapies for r/r B-ALL and discuss considerations for their use.

Original language	English (US)
Pages (from-to)	666-680
Number of pages	15
Journal	American journal of hematology
Volume	98
Issue number	4
DOIs	https://doi.org/10.1002/ajh.26853
State	Published - Apr 2023

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26853

Cite this

@article{d158aa4bb080402ead01314ac691d448,

title = "Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia",

abstract = "The recent approvals of four CD19-or CD22-targeted therapies for B-cell acute lymphoblastic leukemia (B-ALL) have transformed the treatment of relapsed/refractory (r/r) disease. Adults with r/r B-ALL are usually eligible for all options, but there are no studies directly comparing these agents, and the treating physician must decide which to select. Each therapy has notable activity as a single agent but has limitations in particular settings, and the optimal choice varies. These therapies can be complementary and used either sequentially or concomitantly. Here, we review the current landscape of antigen-targeted therapies for r/r B-ALL and discuss considerations for their use.",

author = "Ibrahim Aldoss and Shah, {Bijal D.} and Park, {Jae H.} and Lori Muffly and Logan, {Aaron C.} and Patrick Brown and Wendy Stock and Jabbour, {Elias J.}",

note = "Funding Information: The authors thank Mary Clark for assistance in editing the manuscript. Publisher Copyright: {\textcopyright} 2023 Wiley Periodicals LLC.",

year = "2023",

month = apr,

doi = "10.1002/ajh.26853",

language = "English (US)",

volume = "98",

pages = "666--680",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

AU - Aldoss, Ibrahim

AU - Shah, Bijal D.

AU - Park, Jae H.

AU - Muffly, Lori

AU - Logan, Aaron C.

AU - Brown, Patrick

AU - Stock, Wendy

AU - Jabbour, Elias J.

PY - 2023/4

Y1 - 2023/4

N2 - The recent approvals of four CD19-or CD22-targeted therapies for B-cell acute lymphoblastic leukemia (B-ALL) have transformed the treatment of relapsed/refractory (r/r) disease. Adults with r/r B-ALL are usually eligible for all options, but there are no studies directly comparing these agents, and the treating physician must decide which to select. Each therapy has notable activity as a single agent but has limitations in particular settings, and the optimal choice varies. These therapies can be complementary and used either sequentially or concomitantly. Here, we review the current landscape of antigen-targeted therapies for r/r B-ALL and discuss considerations for their use.

AB - The recent approvals of four CD19-or CD22-targeted therapies for B-cell acute lymphoblastic leukemia (B-ALL) have transformed the treatment of relapsed/refractory (r/r) disease. Adults with r/r B-ALL are usually eligible for all options, but there are no studies directly comparing these agents, and the treating physician must decide which to select. Each therapy has notable activity as a single agent but has limitations in particular settings, and the optimal choice varies. These therapies can be complementary and used either sequentially or concomitantly. Here, we review the current landscape of antigen-targeted therapies for r/r B-ALL and discuss considerations for their use.

UR - http://www.scopus.com/inward/record.url?scp=85147509507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147509507&partnerID=8YFLogxK

U2 - 10.1002/ajh.26853

DO - 10.1002/ajh.26853

M3 - Review article

C2 - 36691748

AN - SCOPUS:85147509507

SN - 0361-8609

VL - 98

SP - 666

EP - 680

JO - American journal of hematology

JF - American journal of hematology

IS - 4

ER -

Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this